Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2013

01.11.2013 | Gynecologic Oncology

The four steps in the prevention of human papillomavirus-associated neoplasia

Considerations for preventive measures, screening, disease impact, and potential overtreatments in HPV-related pathology

verfasst von: Carlo A. Liverani

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

There is no cure currently available for HPV infections, although ablative and excisional treatments of some dysplasias often result in a clinical and virological cure. Effective control measures of HPV-associated cancers rely on the prevention at four different levels. Apart from sexual abstinence, primary prevention is realized through vaccines targeting the most frequent HPV types: negative attitudes towards HPV vaccination and high costs are the main obstacles. The aim of secondary prevention is to detect precancerous changes before they develop into invasive cancer, while tertiary prevention involves actual treatment of high-grade lesions: in many countries routine screening with cytology is being challenged with HPV DNA testing. Quaternary prevention comprehends those actions adopted to mitigate or avoid unnecessary or excessive medical interventions, and may well be addressed in avoiding treatments for low-grade intraepithelial neoplasia. Though some gynecologists commonly recommend treatment for low-grade disease and women tend to prefer active management if not properly informed, harms arising from unnecessary treatments, increased costs, work overload for second-level health services, and induced psychosocial distress are causing on-going problems. Prevention efforts of genital HPV-associated cancers should concentrate in: (1) enhancing primary prevention through vaccination of all eligible subjects, (2) achieving high levels of adherence to routine screening programs, (3) treating precancerous lesions, and (4) monitoring current guidelines recommendations to avoid overtreatments. Novel research projects should be designed to study the delicate mechanisms of immune response to HPV.
Literatur
1.
Zurück zum Zitat de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324:17–27PubMed de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324:17–27PubMed
2.
Zurück zum Zitat Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107(2 Suppl 1):S2–S5PubMed Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107(2 Suppl 1):S2–S5PubMed
3.
Zurück zum Zitat Ganguly N, Parihar SP (2009) Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 34(1):113–123PubMed Ganguly N, Parihar SP (2009) Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 34(1):113–123PubMed
4.
Zurück zum Zitat Shew M, Ermel A, Weaver B, Denski C, Tong Y, Tu W, Fortenberry JD, Qadadri B, Brown D (2011) HPV detection from adolescent women with prolonged follow-up. 27th International papillomavirus conference. Berlin, Epidemiology/Public Health Abstract Book; 08.07:160p Shew M, Ermel A, Weaver B, Denski C, Tong Y, Tu W, Fortenberry JD, Qadadri B, Brown D (2011) HPV detection from adolescent women with prolonged follow-up. 27th International papillomavirus conference. Berlin, Epidemiology/Public Health Abstract Book; 08.07:160p
5.
Zurück zum Zitat Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19PubMed Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19PubMed
6.
Zurück zum Zitat Zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384(2):260–265PubMed Zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384(2):260–265PubMed
7.
Zurück zum Zitat Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J et al (2010) A population-based prospective study of carcinogenic human papillomavirus (HPV) variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70(8):3159–3169PubMed Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J et al (2010) A population-based prospective study of carcinogenic human papillomavirus (HPV) variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70(8):3159–3169PubMed
8.
Zurück zum Zitat Widdice LE (2012) Human papillomavirus disease in adolescents: management and prevention. Adolesc Med State Art Rev 23(1):192–206PubMed Widdice LE (2012) Human papillomavirus disease in adolescents: management and prevention. Adolesc Med State Art Rev 23(1):192–206PubMed
9.
Zurück zum Zitat de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7:453–459PubMed de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7:453–459PubMed
10.
Zurück zum Zitat Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE (2011) Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003–2006. J Infect Dis 204(4):566–573PubMed Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE (2011) Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003–2006. J Infect Dis 204(4):566–573PubMed
11.
Zurück zum Zitat Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, Liaw KL, Nygård J, Nygård M (2007) The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 196(10):1447–1454PubMed Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, Liaw KL, Nygård J, Nygård M (2007) The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 196(10):1447–1454PubMed
12.
Zurück zum Zitat Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL et al (2012) EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 131(9):1969–1982PubMed Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL et al (2012) EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 131(9):1969–1982PubMed
13.
Zurück zum Zitat Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM (1991) Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265(4):472–477PubMed Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM (1991) Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265(4):472–477PubMed
14.
Zurück zum Zitat Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL (2001) Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184(12):1508–1517PubMed Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL (2001) Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184(12):1508–1517PubMed
15.
Zurück zum Zitat Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, Rohan TE (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180(5):1415–1423PubMed Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, Rohan TE (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180(5):1415–1423PubMed
16.
Zurück zum Zitat Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M et al (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92(6):464–474PubMed Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M et al (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92(6):464–474PubMed
17.
Zurück zum Zitat Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370(9590):890–907PubMed Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370(9590):890–907PubMed
18.
Zurück zum Zitat Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111(2):278–285PubMed Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111(2):278–285PubMed
19.
Zurück zum Zitat Maglennon GA, McIntosh P, Doorbar J (2011) Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414(2):153–163PubMed Maglennon GA, McIntosh P, Doorbar J (2011) Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414(2):153–163PubMed
20.
Zurück zum Zitat Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE (2012) Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 72(23):6183–6190PubMed Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE (2012) Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 72(23):6183–6190PubMed
21.
Zurück zum Zitat Ault KA (2006) Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006(Suppl):40470PubMed Ault KA (2006) Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006(Suppl):40470PubMed
22.
Zurück zum Zitat Manhart LE, Koutsky LA (2002) Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29(11):725–735PubMed Manhart LE, Koutsky LA (2002) Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29(11):725–735PubMed
23.
Zurück zum Zitat Fehrmann F, Laimins LA (2003) Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22(33):5201–5207PubMed Fehrmann F, Laimins LA (2003) Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22(33):5201–5207PubMed
24.
Zurück zum Zitat Zur Hausen H (1999) Papillomaviruses in human cancers. Proc Assoc Am Phys 111:1–7 Zur Hausen H (1999) Papillomaviruses in human cancers. Proc Assoc Am Phys 111:1–7
25.
Zurück zum Zitat Zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698PubMed Zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698PubMed
26.
Zurück zum Zitat Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci Lond 110(5):525–541PubMed Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci Lond 110(5):525–541PubMed
27.
Zurück zum Zitat Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151:1158–1171PubMed Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151:1158–1171PubMed
28.
Zurück zum Zitat Koutsky LA, Galloway DA, Holmes KK (1988) Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10:122–163PubMed Koutsky LA, Galloway DA, Holmes KK (1988) Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10:122–163PubMed
29.
Zurück zum Zitat Dunne EF, Unger ER, Sternberg M, Mc Quillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 287(8):813–819 Dunne EF, Unger ER, Sternberg M, Mc Quillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 287(8):813–819
30.
Zurück zum Zitat Winer RL, Feng Q, Hughes JP, O’Reilly S, Kiviat NB, Koutsky LA (2008) Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197(2):279–282PubMed Winer RL, Feng Q, Hughes JP, O’Reilly S, Kiviat NB, Koutsky LA (2008) Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197(2):279–282PubMed
31.
Zurück zum Zitat Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186:1396–1402PubMed Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186:1396–1402PubMed
32.
Zurück zum Zitat Gravitt PE (2011) The known unknowns of HPV natural history. J Clin Invest 121(12):4593–4599PubMed Gravitt PE (2011) The known unknowns of HPV natural history. J Clin Invest 121(12):4593–4599PubMed
33.
Zurück zum Zitat Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M (2008) An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL triage study (ALTS). Obstet Gynecol 111(4):847–856PubMed Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M (2008) An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL triage study (ALTS). Obstet Gynecol 111(4):847–856PubMed
34.
Zurück zum Zitat Liverani CA, Ciavattini A, Monti E, Puglia D, Mangano S, Di Giuseppe J, Zizzi A, Goteri G, Bolis G (2012) High risk HPV DNA subtypes and E6/E7 mRNA expression in a cohort of colposcopy patients from Northern Italy with high-grade histologically verified cervical lesions. Am J Transl Res 4(4):452–457 Liverani CA, Ciavattini A, Monti E, Puglia D, Mangano S, Di Giuseppe J, Zizzi A, Goteri G, Bolis G (2012) High risk HPV DNA subtypes and E6/E7 mRNA expression in a cohort of colposcopy patients from Northern Italy with high-grade histologically verified cervical lesions. Am J Transl Res 4(4):452–457
35.
Zurück zum Zitat Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, Gostout BS, Persing DH (2002) Host genetic polymorphism analysis in cervical Cancer. Clin Chem 48(8):1218–1224PubMed Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, Gostout BS, Persing DH (2002) Host genetic polymorphism analysis in cervical Cancer. Clin Chem 48(8):1218–1224PubMed
36.
Zurück zum Zitat Oldstone MBA (2009) Anatomy of viral persistence. PLoS Pathog 5(7):e1000523PubMed Oldstone MBA (2009) Anatomy of viral persistence. PLoS Pathog 5(7):e1000523PubMed
37.
Zurück zum Zitat Füle T, Máthé M, Suba Z, Csapó Z, Szarvas T, Tátrai P, Paku S, Kovalszky I (2006) The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. Virology 348(2):289–296PubMed Füle T, Máthé M, Suba Z, Csapó Z, Szarvas T, Tátrai P, Paku S, Kovalszky I (2006) The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. Virology 348(2):289–296PubMed
38.
Zurück zum Zitat Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ (2002) ASCCP-sponsored consensus conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287(16):2120–2129PubMed Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ (2002) ASCCP-sponsored consensus conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287(16):2120–2129PubMed
39.
Zurück zum Zitat Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N, Forum group members; bethesda 2001 workshop (2002) The 2001 bethesda system: terminology for reporting results of cervical cytology. JAMA 287:2114–2119PubMed Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N, Forum group members; bethesda 2001 workshop (2002) The 2001 bethesda system: terminology for reporting results of cervical cytology. JAMA 287:2114–2119PubMed
40.
Zurück zum Zitat Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody (2004) Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med 128(11):1224–1229PubMed Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody (2004) Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med 128(11):1224–1229PubMed
41.
Zurück zum Zitat Munk AC, Kruse AJ, van Diermen B, Janssen EA, Skaland I, Gudlaugsson E, Nilsen ST, Baak JP (2007) Cervical intraepithelial grade 3 lesions can regress. APMIS 115(12):1409–1414PubMed Munk AC, Kruse AJ, van Diermen B, Janssen EA, Skaland I, Gudlaugsson E, Nilsen ST, Baak JP (2007) Cervical intraepithelial grade 3 lesions can regress. APMIS 115(12):1409–1414PubMed
42.
Zurück zum Zitat Holowaty P, Miller AB, Rohan T, To T (1999) Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91(3):252–258PubMed Holowaty P, Miller AB, Rohan T, To T (1999) Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91(3):252–258PubMed
43.
Zurück zum Zitat Barbisan G, Pérez LO, Contreras A, Golijow CD (2012) TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol 33(5):1549–1556PubMed Barbisan G, Pérez LO, Contreras A, Golijow CD (2012) TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol 33(5):1549–1556PubMed
44.
Zurück zum Zitat Frey MK, Gupta D (2011) Evaluation of women with atypical glandular cells on cervical cytology. Gynecol Oncol 36(9):23–29 Frey MK, Gupta D (2011) Evaluation of women with atypical glandular cells on cervical cytology. Gynecol Oncol 36(9):23–29
45.
Zurück zum Zitat Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D (2007) 2006 ASCCP-sponsored consensus conference2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11(4):201–222PubMed Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D (2007) 2006 ASCCP-sponsored consensus conference2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11(4):201–222PubMed
46.
Zurück zum Zitat Massad LS (2008) Assessing new technologies for cervical cancer screening: beyond sensitivity. J Low Genit Tract Dis 12:311–315PubMed Massad LS (2008) Assessing new technologies for cervical cancer screening: beyond sensitivity. J Low Genit Tract Dis 12:311–315PubMed
47.
Zurück zum Zitat Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M (2013) The HPV test has similar sensitivity but more overdiagnosis than the Pap test—A randomised health services study on cervical cancer screening in Finland. Int J Cancer 132(9):2141–2147PubMed Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M (2013) The HPV test has similar sensitivity but more overdiagnosis than the Pap test—A randomised health services study on cervical cancer screening in Finland. Int J Cancer 132(9):2141–2147PubMed
48.
Zurück zum Zitat Moyer VA (2012) On behalf of the U.S. preventive services task force. Screening for cervical cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 156(12):880–891PubMed Moyer VA (2012) On behalf of the U.S. preventive services task force. Screening for cervical cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 156(12):880–891PubMed
49.
Zurück zum Zitat Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FAR, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER (2012) American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3):147–172PubMed Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FAR, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER (2012) American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3):147–172PubMed
50.
Zurück zum Zitat Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW, For the 2012 ASCCP Consensus Guidelines Conference (2013) 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 121(4):829–846PubMed Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW, For the 2012 ASCCP Consensus Guidelines Conference (2013) 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 121(4):829–846PubMed
51.
Zurück zum Zitat Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J, and the Athena HPV Study Group (2013) Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 208:184.e1–184.e11 Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J, and the Athena HPV Study Group (2013) Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 208:184.e1–184.e11
52.
Zurück zum Zitat Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA (2009) HPV screening for cervical cancer in rural India. N Eng J Med 360(14):1385–1394 Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA (2009) HPV screening for cervical cancer in rural India. N Eng J Med 360(14):1385–1394
53.
Zurück zum Zitat Rebolj M, Lynge E (2010) Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Screen 17:1–2PubMed Rebolj M, Lynge E (2010) Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Screen 17:1–2PubMed
54.
Zurück zum Zitat Kitchener HC, Altamonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10(7):672–682PubMed Kitchener HC, Altamonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10(7):672–682PubMed
55.
Zurück zum Zitat Patanwala IY, Bauer HM, Miyamoto J, Park IU, Huchko MJ, Smith-McCune KK (2013) A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening. Am J Obstet Gynecol 208(5):343–353PubMed Patanwala IY, Bauer HM, Miyamoto J, Park IU, Huchko MJ, Smith-McCune KK (2013) A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening. Am J Obstet Gynecol 208(5):343–353PubMed
56.
Zurück zum Zitat Lee JW, Berkowitz Z, Saraiya M (2011) Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 118(1):4–13PubMed Lee JW, Berkowitz Z, Saraiya M (2011) Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 118(1):4–13PubMed
57.
Zurück zum Zitat Castle PE (2011) Abuses in human papillomavirus DNA Testing. Obstet Gynecol 118(1):1–3PubMed Castle PE (2011) Abuses in human papillomavirus DNA Testing. Obstet Gynecol 118(1):1–3PubMed
58.
Zurück zum Zitat Frederiksen ME, Lynge E, Rebolj M (2012) What women want? Women’s preferences for the management of low-grade abnormal cervical screening tests: a systematic review. BJOG 119:7–19PubMed Frederiksen ME, Lynge E, Rebolj M (2012) What women want? Women’s preferences for the management of low-grade abnormal cervical screening tests: a systematic review. BJOG 119:7–19PubMed
59.
Zurück zum Zitat Kitchener HC, Paraskevaidis E (2012) Patient’s preference: a sound basis for policy? BJOG 119(1):5–6PubMed Kitchener HC, Paraskevaidis E (2012) Patient’s preference: a sound basis for policy? BJOG 119(1):5–6PubMed
60.
Zurück zum Zitat Solomon D, Papillo JL, Davey DD, Atkison K, Bibbo M, Birdsong G, Bonfiglio T, Howell L, Jenkins E, Savaloja L, Wilbur D (2009) Cytopathology education and technology consortium. Statement on HPV DNA test utilization. Acta Cytol 53(3):247–248 (discussion 249–252)PubMed Solomon D, Papillo JL, Davey DD, Atkison K, Bibbo M, Birdsong G, Bonfiglio T, Howell L, Jenkins E, Savaloja L, Wilbur D (2009) Cytopathology education and technology consortium. Statement on HPV DNA test utilization. Acta Cytol 53(3):247–248 (discussion 249–252)PubMed
61.
Zurück zum Zitat Jakobsson M, Gissler M, Paavonen J, Tapper AM (2009) Loop electrosurgical excision procedure and the risk for preterm birth. Obstet Gynecol 114(3):504–510PubMed Jakobsson M, Gissler M, Paavonen J, Tapper AM (2009) Loop electrosurgical excision procedure and the risk for preterm birth. Obstet Gynecol 114(3):504–510PubMed
62.
Zurück zum Zitat Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK (2009) Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period. Am J Obstet Gynecol 201(1):33.e1–33.e6 Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK (2009) Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period. Am J Obstet Gynecol 201(1):33.e1–33.e6
63.
Zurück zum Zitat Bruinsma FJ, Quinn MA (2011) The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 118(9):1031–1041PubMed Bruinsma FJ, Quinn MA (2011) The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 118(9):1031–1041PubMed
64.
Zurück zum Zitat Poon LC, Savvas M, Zamblera D, Skyfta E, Nicolaides KH (2012) Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery. BJOG 119(6):692–698PubMed Poon LC, Savvas M, Zamblera D, Skyfta E, Nicolaides KH (2012) Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery. BJOG 119(6):692–698PubMed
65.
Zurück zum Zitat Stock SJ, Norman JE (2012) Treatments for precursors of cervical cancer and preterm labour. BJOG 119(6):647–649PubMed Stock SJ, Norman JE (2012) Treatments for precursors of cervical cancer and preterm labour. BJOG 119(6):647–649PubMed
66.
Zurück zum Zitat Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, Kyrgiou M, Harrity C, Arbyn M, Prendiville W (2012) The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. BJOG 119(6):685–691PubMed Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, Kyrgiou M, Harrity C, Arbyn M, Prendiville W (2012) The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. BJOG 119(6):685–691PubMed
67.
Zurück zum Zitat Phadnis SV, Atilade A, Young MP, Evans H, Walker PG (2010) The volume perspective: a comparison of two excisional treatments for cervical intraepithelial neoplasia (laser versus LLETZ). BJOG 117(5):615–619PubMed Phadnis SV, Atilade A, Young MP, Evans H, Walker PG (2010) The volume perspective: a comparison of two excisional treatments for cervical intraepithelial neoplasia (laser versus LLETZ). BJOG 117(5):615–619PubMed
68.
Zurück zum Zitat Heinonen A, Gissler M, Riska A, Paavonen J, Tapper AM, Jakobsson M (2013) Loop electrosurgical excision procedure and the risk for preterm delivery. Obstet Gynecol 121:1063–1068PubMed Heinonen A, Gissler M, Riska A, Paavonen J, Tapper AM, Jakobsson M (2013) Loop electrosurgical excision procedure and the risk for preterm delivery. Obstet Gynecol 121:1063–1068PubMed
69.
Zurück zum Zitat Hamashima C, Aoki D, Miyagi E, Saito E, Nakayama T, Sagawa M, Saito H, Sobue T (2010) The Japanese guideline for cervical cancer screening. Jpn J Clin Oncol 40(6):485–502PubMed Hamashima C, Aoki D, Miyagi E, Saito E, Nakayama T, Sagawa M, Saito H, Sobue T (2010) The Japanese guideline for cervical cancer screening. Jpn J Clin Oncol 40(6):485–502PubMed
71.
Zurück zum Zitat Canadian Task Force on Preventive Health Care (2013) Recommendations on screening for cervical cancer. CMAJ 185(1):35–45 Canadian Task Force on Preventive Health Care (2013) Recommendations on screening for cervical cancer. CMAJ 185(1):35–45
72.
Zurück zum Zitat Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF (2010) Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol 116(5):1158–1170PubMed Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF (2010) Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol 116(5):1158–1170PubMed
73.
Zurück zum Zitat Tan JH, Garland SM, Tabrizi SN, Moore EE, Danielewski JA, Quinn MA (2013) Hybrid capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 17(3):308–314 (in press)PubMed Tan JH, Garland SM, Tabrizi SN, Moore EE, Danielewski JA, Quinn MA (2013) Hybrid capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 17(3):308–314 (in press)PubMed
74.
Zurück zum Zitat Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U et al (2009) HPV PATRICIA study group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccines against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314PubMed Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U et al (2009) HPV PATRICIA study group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccines against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314PubMed
75.
Zurück zum Zitat FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown, Koutsky LA, Tay EH, García P, Ault KA et al (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493. doi:10.1136/bmj.c3493 PubMed FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown, Koutsky LA, Tay EH, García P, Ault KA et al (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493. doi:10.​1136/​bmj.​c3493 PubMed
76.
Zurück zum Zitat Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM et al (2007) Gynecologic cancer advisory group, Garcia F. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57(1):7–28PubMed Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM et al (2007) Gynecologic cancer advisory group, Garcia F. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57(1):7–28PubMed
77.
Zurück zum Zitat Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE (2011) The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29(46):8443–8450PubMed Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE (2011) The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29(46):8443–8450PubMed
78.
Zurück zum Zitat Small SL, Patel DA (2012) Impact of HPV vaccine availability on uptake. J Nurse Practitioners 8(1):61–66 Small SL, Patel DA (2012) Impact of HPV vaccine availability on uptake. J Nurse Practitioners 8(1):61–66
79.
Zurück zum Zitat Sheinfeld Gorin SN, Glenn BA, Perkins RB (2011) The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Adv Ther 28(8):615–639PubMed Sheinfeld Gorin SN, Glenn BA, Perkins RB (2011) The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Adv Ther 28(8):615–639PubMed
80.
Zurück zum Zitat Mazzadi A, Paolino M, Arrossi S (2012) HPV vaccine acceptability and knowledge among gynecologists in Argentina. Salud Publica Mex 54(5):515–522PubMed Mazzadi A, Paolino M, Arrossi S (2012) HPV vaccine acceptability and knowledge among gynecologists in Argentina. Salud Publica Mex 54(5):515–522PubMed
81.
Zurück zum Zitat Kane MA (2012) Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res (Phila) 5(1):24–29 Kane MA (2012) Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res (Phila) 5(1):24–29
82.
Zurück zum Zitat Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: a randomized clinical trial. JAMA 309(17):1793–1802PubMed Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: a randomized clinical trial. JAMA 309(17):1793–1802PubMed
83.
Zurück zum Zitat Kahn JA, Bernstein DI (2013) HPV vaccination: too soon for 2 doses? JAMA 309(17):1832–1834PubMed Kahn JA, Bernstein DI (2013) HPV vaccination: too soon for 2 doses? JAMA 309(17):1832–1834PubMed
84.
Zurück zum Zitat Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B et al (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101:88–99PubMed Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B et al (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101:88–99PubMed
85.
Zurück zum Zitat de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegooijen M (2012) Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344:e670. doi:10.1136/bmj.e670 PubMed de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegooijen M (2012) Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344:e670. doi:10.​1136/​bmj.​e670 PubMed
86.
Zurück zum Zitat Feldman S (2011) Making sense of the new cervical-cancer screening guidelines. N Engl J Med 365(23):2145–2147PubMed Feldman S (2011) Making sense of the new cervical-cancer screening guidelines. N Engl J Med 365(23):2145–2147PubMed
87.
Zurück zum Zitat Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, Lee DW, Kim SW, Kim JH, Kim YT, Kim S, Kim JW (2008) Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol 19(3):162–168PubMed Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, Lee DW, Kim SW, Kim JH, Kim YT, Kim S, Kim JW (2008) Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol 19(3):162–168PubMed
88.
Zurück zum Zitat Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z (2011) IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 35:1638–1645PubMed Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z (2011) IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 35:1638–1645PubMed
89.
Zurück zum Zitat Ovestad IT, Vennestrøm U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, Feng W, Voorhorst F, Janssen EA, Baak JP (2011) Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol 123(2):278–283PubMed Ovestad IT, Vennestrøm U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, Feng W, Voorhorst F, Janssen EA, Baak JP (2011) Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol 123(2):278–283PubMed
90.
Zurück zum Zitat Gofrit ON, Shemer J, Leibovici D, Modan B, Shapira SC (2000) Quaternary prevention: a new look at an old challenge. Isr Med Assoc J 2(7):498–500PubMed Gofrit ON, Shemer J, Leibovici D, Modan B, Shapira SC (2000) Quaternary prevention: a new look at an old challenge. Isr Med Assoc J 2(7):498–500PubMed
91.
Zurück zum Zitat CDC Atlanta—Sexually Transmitted Diseases Treatment Guidelines (2010) MMWR 59 (No RR-12):69–78 CDC Atlanta—Sexually Transmitted Diseases Treatment Guidelines (2010) MMWR 59 (No RR-12):69–78
92.
Zurück zum Zitat Lee C, Mancuso V, Contant T, Jackson R, Smith-Mccune K (2003) Treatment of women with low-grade squamous intraepithelial lesions on cytologic evidence or biopsy result by board-certified gynecologists. Am J Obstet Gynecol 188(3):693–698PubMed Lee C, Mancuso V, Contant T, Jackson R, Smith-Mccune K (2003) Treatment of women with low-grade squamous intraepithelial lesions on cytologic evidence or biopsy result by board-certified gynecologists. Am J Obstet Gynecol 188(3):693–698PubMed
93.
Zurück zum Zitat Gross G (2001) Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions. Hautarzt 52(1):6–17PubMed Gross G (2001) Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions. Hautarzt 52(1):6–17PubMed
94.
Zurück zum Zitat Wolf R, Davidovici B (2010) Treatment of genital warts: facts and controversies. Clin Dermatol 28(5):546–548PubMed Wolf R, Davidovici B (2010) Treatment of genital warts: facts and controversies. Clin Dermatol 28(5):546–548PubMed
96.
Zurück zum Zitat Gérvas J, Starfield B, Heath I (2008) Is clinical prevention better than cure? Lancet 372:1997–1999PubMed Gérvas J, Starfield B, Heath I (2008) Is clinical prevention better than cure? Lancet 372:1997–1999PubMed
98.
Zurück zum Zitat Moyer VA (2012) What we don’t know can hurt our patients: physician innumeracy and overuse of screening tests. Ann Intern Med 156:392–393PubMed Moyer VA (2012) What we don’t know can hurt our patients: physician innumeracy and overuse of screening tests. Ann Intern Med 156:392–393PubMed
99.
Zurück zum Zitat Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605–613PubMed Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605–613PubMed
100.
Zurück zum Zitat Kahn JA, Slap GB, Bernstein DI, Kollar LM, Tissot AM, Hillard PA, Rosenthal SL (2005) Psychological, behavioural and interpersonal impact of human papillomavirus and Pap test results. J Womens Health 14(7):650–659 Kahn JA, Slap GB, Bernstein DI, Kollar LM, Tissot AM, Hillard PA, Rosenthal SL (2005) Psychological, behavioural and interpersonal impact of human papillomavirus and Pap test results. J Womens Health 14(7):650–659
101.
Zurück zum Zitat Arrossi S, Wiesner C (2012) The psychological and social costs of HPV testing in screening activities. HPV Today N 27, Nov Arrossi S, Wiesner C (2012) The psychological and social costs of HPV testing in screening activities. HPV Today N 27, Nov
102.
Zurück zum Zitat Rosen NO, Knäuper B, Di Dio P, Morrison E, Tabing R, Feldstain A, Amsel R, Mayrand MH, Franco EL, Rosberger Z (2010) The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: a randomised controlled study. Psychol Health 25(6):651–668PubMed Rosen NO, Knäuper B, Di Dio P, Morrison E, Tabing R, Feldstain A, Amsel R, Mayrand MH, Franco EL, Rosberger Z (2010) The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: a randomised controlled study. Psychol Health 25(6):651–668PubMed
103.
Zurück zum Zitat Kwan TT, Cheung AN, Lo SS, Lee PW, Tam KF, Chan KK, Ngan HY (2011) Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet Gynecol Scand 90(5):445–451PubMed Kwan TT, Cheung AN, Lo SS, Lee PW, Tam KF, Chan KK, Ngan HY (2011) Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet Gynecol Scand 90(5):445–451PubMed
104.
Zurück zum Zitat Erickson BK, Alvarez RD, Huh WK (2013) Human papillomavirus: what every provider should know. Am J Obstet Gynecol 208(3):169–175PubMed Erickson BK, Alvarez RD, Huh WK (2013) Human papillomavirus: what every provider should know. Am J Obstet Gynecol 208(3):169–175PubMed
105.
Zurück zum Zitat Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS (2009) Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85(7):499–502PubMed Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS (2009) Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85(7):499–502PubMed
106.
Zurück zum Zitat Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 87(7):544–547PubMed Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 87(7):544–547PubMed
107.
Zurück zum Zitat Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032. doi:10.1136/bmj.f2032 PubMed Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032. doi:10.​1136/​bmj.​f2032 PubMed
109.
Zurück zum Zitat Kreimer AR, Chaturvedi AK (2011) HPV-associated oropharyngeal Cancers—are they preventable? Cancer Prev Res (Phila) 4(9):1346–1349 Kreimer AR, Chaturvedi AK (2011) HPV-associated oropharyngeal Cancers—are they preventable? Cancer Prev Res (Phila) 4(9):1346–1349
110.
Zurück zum Zitat Jin XW, Lipold L, Sikon A, Rome E (2013) Human papillomavirus vaccine: safe, effective, underused. Cleve Clin J Med 80(1):49–60PubMed Jin XW, Lipold L, Sikon A, Rome E (2013) Human papillomavirus vaccine: safe, effective, underused. Cleve Clin J Med 80(1):49–60PubMed
Metadaten
Titel
The four steps in the prevention of human papillomavirus-associated neoplasia
Considerations for preventive measures, screening, disease impact, and potential overtreatments in HPV-related pathology
verfasst von
Carlo A. Liverani
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2013
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-3011-9

Weitere Artikel der Ausgabe 5/2013

Archives of Gynecology and Obstetrics 5/2013 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.